View in EDS HTML Full Text PDF Full Text

The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.

Saved in:
Bibliographic Details
Title: The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.
Authors: Strijbis EM; Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Repovic P; Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA., Mostert J; Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands., Bowen JD; Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA., Uitdehaag BM; Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Cutter G; Department of Biostatistics, The University of Alabama at Birmingham, Birmingham, AL, USA., Koch MW; Departments of Clinical Neurosciences and Community Health Sciences, University of Calgary, Calgary, AB, Canada.
Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2022 Sep; Vol. 28 (10), pp. 1606-1619.
Publication Type: Journal Article
Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35876467
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Strijbis+EM%22">Strijbis EM</searchLink>; Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Repovic+P%22">Repovic P</searchLink>; Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Mostert+J%22">Mostert J</searchLink>; Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Bowen+JD%22">Bowen JD</searchLink>; Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Uitdehaag+BM%22">Uitdehaag BM</searchLink>; Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Cutter+G%22">Cutter G</searchLink>; Department of Biostatistics, The University of Alabama at Birmingham, Birmingham, AL, USA.<br /><searchLink fieldCode="AU" term="%22Koch+MW%22">Koch MW</searchLink>; Departments of Clinical Neurosciences and Community Health Sciences, University of Calgary, Calgary, AB, Canada.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229509185%22">Multiple sclerosis (Houndmills, Basingstoke, England)</searchLink> [Mult Scler] 2022 Sep; Vol. 28 (10), pp. 1606-1619.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22SAGE+Publications%22">SAGE Publications </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9509185 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1477-0970 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213524585%22">13524585 </searchLink><i>NLM ISO Abbreviation: </i>Mult Scler <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35876467
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/13524585221105465
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1606
    Titles:
      – TitleFull: The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Strijbis EM
      – PersonEntity:
          Name:
            NameFull: Repovic P
      – PersonEntity:
          Name:
            NameFull: Mostert J
      – PersonEntity:
          Name:
            NameFull: Bowen JD
      – PersonEntity:
          Name:
            NameFull: Uitdehaag BM
      – PersonEntity:
          Name:
            NameFull: Cutter G
      – PersonEntity:
          Name:
            NameFull: Koch MW
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2022 Sep
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1477-0970
          Numbering:
            – Type: volume
              Value: 28
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Multiple sclerosis (Houndmills, Basingstoke, England)
              Type: main
ResultId 1